MedTrace Logo

Study of ONO-8577 in Patients With Overactive Bladder

NCT03106623 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2024-05-03

No results posted yet for this study

Summary

The objective of the study is to evaluate the efficacy and safety of ONO-8577 compared to combination of solifenacin succinate and mirabegron or placebo for overactive bladder

Conditions

Interventions

DRUG

ONO-8577

Oral administration of ONO-8577 once a daily for 4 weeks

DRUG

solifenacin succinate + mirabegron

Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks

DRUG

Placebo

Oral administration of Placebo once a daily for 4 weeks

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Hitoshi Kajitani · Ono Pharmaceutical Co. Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-07
Primary Completion
2017-08-29
Completion
2017-09-26

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03106623 on ClinicalTrials.gov